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Abstract
AIM: To evaluate the incidence of late biliary compli-
cations in non-resectable alveolar echinococcosis (AE) 
under long-term chemotherapy with benzimidazoles.
METHODS: Retrospective analysis of AE patients with 
biliary complications occurring more than three years 
after the diagnosis of AE. We compared characteristics 
of patients with and without biliary complications, ana-
lyzed potential risk factor for biliary complications and 
performed survival analyses.
RESULTS: Ninety four of 148 patients with AE in Zu-
rich had non-resectable AE requiring long-term benz-
imidazole chemotherapy, of which 26 (28%) patients 
developed late biliary complications. These patients 
had a median age of 55.5 (35.5-65) years at diagno-
sis of AE and developed biliary complications after 15 
(8.25-19) years of chemotherapy. The most common 
biliary complications during long-term chemotherapy 
were late-onset cholangitis (n  = 14), sclerosing 
cholangitis-like lesions (n  = 8), hepatolithiasis (n  = 5), 
affection of the common bile duct (n  = 7) and second-
ary biliary cirrhosis (n  = 7). Thirteen of the 26 patients 
had undergone surgery (including 12 resections) be-
fore chemotherapy. Previous surgery was a risk factor 
for late biliary complications in linear regression analy-
sis (P  = 0.012).
CONCLUSION: Late biliary complications can be ob-
served in nearly one third of patients with non-resect-
able AE, with previous surgery being a potential risk 
factor. After the occurrence of late biliary complica-
tions, the median survival is only 3 years, suggesting 
that late biliary complications indicate a poor prognos-
tic outcome.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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INTRODUCTION
Human alveolar echinococcosis (AE) is caused by the 
larval stage of  the fox tapeworm, Echinococcus multi-
locularis. The parasites’ dominant definitive host is the 
red fox, which can be infected in up to 60%[1]. Echino-
coccus multilocularis is widely distributed throughout 
the Northern Hemisphere, with a disease-endemic area 
stretching from North America through central Europe 
(eastern France, southern Germany, Switzerland and 
western Austria) to central and east Asia[2,3]. AE remains 
a rare disease in Western Europe, but not in highly en-
demic regions such as Sibiria and China, where a human 
prevalence rate of  3% or higher has been described[4].
In early untreated cohorts, the fatality rate exceeded 
90% within 10 years[5]. However, survival rates have im-
proved tremendously within the last three decades due 
to the increasing success of  several treatment options, 
including surgery as the preferred first line therapy[6], 
long-term chemotherapy with benzimidazoles (avail-
able since 1975[7]), interventional procedures, and in rare 
cases liver transplantation[8]. As a result, the life expec-
tancy for a middle aged patient with AE has increased 
by approximately 20 years and is now only slightly re-
duced (by about 3 years) compared to healthy controls[7]. 
However, if  complete surgical resection of  the parasite 
is not possible, long-term (life-long) chemotherapy with 
benzimidazoles remains the standard of  care[6], and AE 
continues to be a disease with significant morbidity and 
mortality.
In unresected AE, biliary complications can influence 
the course of  the disease significantly. The intrahepatic 
bile ducts or the extrahepatic biliary tree can either be 
directly infiltrated and destroyed by the growing parasite 
or compressed due to surrounding growth. Biliary (and 
other) complications include cholangitis, liver abscess, 
septic shock, portal hypertension and biliary cirrhosis[9]. 
Detailed knowledge of  biliary complications is crucial 
for the management of  patients with non-resectable AE. 
Currently, our knowledge of  adverse effects in AE is 
very limited. There are case series describing biliary com-
plications of  cystic hydatid disease (caused by Echino-
coccus granulosus). In these publications, bile duct ob-
struction with liver atrophy in the cyst-bearing lobes[10], 
rupture of  hepatic hydatid cysts in the biliary tree with 
secondary cholangitis[11] or biliary obstruction by daugh-
ter cysts with further complications such as portal hyper-
tension, ascites, abscesses and the development of  bron-
chobiliary fistulas have been described[12,13]. However, 
these data are not directly applicable to alveolar hydatid 
disease (AE; caused by Echinococcus multilocularis) 
which is much more frequent in central Europe. We 
aimed to evaluate late biliary complications in a cohort 
of  patients with non-resectable AE.
MATERIALS AND METHODS
Patients
From the prospective database of  the Swiss National 
Center for Echinococcosis, we retrospectively analysed 
all available data of  AE patients followed at the Univer-
sity Hospital of  Zurich with a diagnosis of  AE before 
2003. The detailed study protocol has been published 
earlier[14]. The study was performed according to the 
declaration of  Helsinki and the protocol was approved 
by the hospital ethics committee. All patients provided 
written informed consent to participate in the study. 
Patients were examined at yearly intervals, including a 
physical examination, routine laboratory tests, and addi-
tional immunodiagnostic tests, a chest radiograph, ultra-
sonography, and CT scan of  the abdomen according to 
the study protocol. Further magnetic resonance imaging 
of  the upper abdomen was performed in unclear cases.
The patient selection process as described above is 
illustrated in Figure 1. All patients in Zurich with a di-
agnosis of  AE between 1967 and 2003 were included (n 
= 148). Fifty-four patients with successful R0 resection 
were excluded. A total of  94 patients had non-resectable 
or recurrent AE and received continuous long-term 
chemotherapy with benzimidazole carbamates (either 
mebendazole or albendazole). Of  the 94 non-resectable 
AE patients, 26 patients developed late biliary complica-
tions as diagnosed by imaging [endoscopic retrograde 
cholangiopancreaticography (ERCP), computed tomog-
raphy scan (CT), magnetic resonance cholangiopancreat-
icography (MRCP)] and blood tests. Liver biopsies were 
not routinely performed in these patients to find biliary 
cirrhosis.
To assess the prognostic value of  late hepatobiliary 
complications, we compared the 26 patients with control 
patients without any biliary complications. The control 
group consisted of  32 patients with a first diagnosis of  
non-resectable AE between 1979 and 2003 and a follow 
up of  at least 3 years.
Definitions
Late biliary complications were defined as biliary disease 
occurring at least 3 years after initial diagnosis of  AE. 
The following were assessed: (1) Sclerosing cholangitis-
like lesions, defined as abnormal ERCP or MRCP find-
ings with features resembling those of  primary scleros-
ing cholangitis such as multilocular annular strictures 
within the intrahepatic and/or extrahepatic bile ducts 
with alternating normal or slightly dilated segments; (2) 
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Stenosis of  the common bile duct, defined as isolated 
strictures in the proximal or distal common bile duct 
as well as strictures in the hilar region or extensions to 
the extrahepatic left and right duct; (3) One or several 
episodes of  late cholangitis; (4) Hepatolithiasis and cho-
ledocholithiasis; (5) Secondary biliary cirrhosis; (6) Post-
operative biliary stenosis after hepaticojejunostomy; and 
(7) Biliary fistulas.
Statistical analysis
Descriptive statistics were calculated using Microsoft Of-
fice Excel 2007. Results of  numerical data are presented 
as medians (quartiles). Group comparisons were per-
formed using the Fisher’s exact test or the Mann-Whit-
ney-U test of  the statistics program GraphPad Prism 5. 
Furthermore, Pearson’s correlation analysis and linear 
regression analysis were done using SPSS. For the linear 
regression analysis the potentially confounding factors: 
gender, age at diagnosis of  AE, years of  follow-up, years 
from diagnosis of  AE until endpoint (either late biliary 
complications or end of  follow-up), years of  albendazole, 
mebendazole and total benzimidazole treatment as well 
as previous surgery were considered.
RESULTS
Characteristics of patients with late biliary complications
Late biliary complications developed in 26 patients with 
non-resectable AE undergoing chemotherapy after a 
median of  15 (interquartile range, IQR: 8.25-19) years. 
The 11 male and 15 female patients had a median age of  
55.5 (35.5-65) years at diagnosis of  AE. Further patient 
characteristics are provided in Table 1, which summa-
rizes patients with and without late biliary complications. 
AE was diagnosed between 1967 and 1997. All patients 
received long-term chemotherapy with benzimidazoles, 
mostly mebendazole (25/26), rarely albendazole (5/26). 
Switching from one benzimidazole to the other was nec-
essary in 4/26 patients. Benzimidazoles were given for a 
median of  13 (IQR: 8.1-20) years.
Late biliary complications
Late biliary complications were grouped according to 
the presenting clinical syndrome or disease and the un-
derlying pathogenic mechanisms. Table 2 summarizes 
the clinical syndromes of  the 26 patient with late biliary 
complications and the respective long-term outcome. 
Symptoms occurred 15 years after diagnosis of  AE at a 
median age of  64.5 (IQR: 54-75 ) years.
Biliary complications included late-onset cholangitis 
(n = 14), sclerosing cholangitis-like lesions (n = 8), he-
paticolithiasis (n = 5), secondary biliary cirrhosis (n = 
7), stenosis of  the common bile duct (n = 2), and post-
operative stenosis after hepaticojejunostomy (n = 1). In 
addition, biliary fistulas occurred in 2 patients, including 
one biliary cutaneous and one bronchobiliary fistula. Al-
together, 44 biliary complications in our 26 patients were 
noted. No obvious associations between different biliary 
complications could be detected. Eleven patients (42%) 
required interventions for late biliary complications, a to-
tal of  23 procedures were performed. 10 patients (38.5%) 
needed ERCP for treatment of  biliary complications. In 
2 patients (7.7%), PTCD was performed. Five patients 
(19.2%) needed surgery, including 3 hepaticojejunosto-
mies and 2 resections. In 1 patient (3.8%), percutaneous 
enterostomy was performed.
36 patients
   Follow-up < 3 year until 2003 (n  = 35)
   Avital AE at first diagnosis (n  = 1)
148 patients in Zurich with 
hepatic AE (first diagnosis until 
2003)
94 patients with non-resectable 
AE, incompletely resected 
AE/relapse
26 patients with late 
hepatobiliary complications
54 patients with 
successful R0 resection
68 patients without late 
hepato-biliary complications
32 control-patients with 
follow-up >3 year
Figure 1  Patient selection process of patients with and a matched control group without biliary complications. Of all patients with hepatic alveolar echinococ-
cosis (AE), patients with successful surgery were excluded. The remaining patients either developed biliary complications or not. From the latter group of patients, 
individuals with insufficient follow up time or avital AE were excluded; the remaining patients were defined as the control group.
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Table 2  Summary of 44 late biliary symptoms and complications occurring in 26 patients and their respective outcome
Table 1  Comparison of patients with and without late biliary complications
Analysis of potential risk factors for late biliary compli-
cations
To identify potential risk factors for late biliary complica-
tions, we performed Pearsons’ correlation and linear re-
gression analysis of  several possible risk factors (Table 3). 
Age at diagnosis of  AE, age at diagnosis of  biliary com-
plications and time from diagnosis of  AE until endpoint 
were not associated with an increased risk. However, 
longer duration of  benzimidazole treatment was associ-
ated with an increased risk of  developing biliary com-
plications, also after adjustment for additional factors in 
the linear regression analysis. Both years of  albendazole 
and mebendazole treatment correlated with the risk for 
the development of  biliary complication even though 
directionality was different with albendazole apparently 
protective and mebendazole increasing the risk. At this 
point, this different directionality is based on very small 
subgroups, difficult to explain and other unknown con-
founding factors could be responsible.
Importantly, previous surgery was a risk factor for 
biliary complications both in the correlation and regres-
sion analysis (P = 0.02 and 0.031, respectively). While 13 
of  the 26 patients with biliary complications had previ-
ously undergone surgery, only 5 out of  32 patients with-
out biliary complications had a history of  surgery. How-
ever, within the biliary complication group, biliary com-
plications were observed both in patients with (n = 13) 
and without previous surgery (n = 13). Surgery was per-
formed shortly after the diagnosis of  AE in 10 patients 
or within the first 5 year after diagnosis in 3 patients (after 
1, 2 and 5 year). Thus, previous surgery seems to be a 
risk factor for late biliary complications, but these are 
nevertheless not simply always consequence of  earlier 
surgical procedures (Table 4).
Survival analysis
A total of  15/26 patients with late biliary complications 
died until the endpoint of  2006. Five of  the 15 deaths 
Patients with late biliary 
complications (n  = 26)
Control group without late biliary 
complications (n  = 32)
P 1 value
Male 42.30% 37.50% NS
Year of AE diagnosis 1967-1997 1979-2003   
Age at AE diagnosis, (yr)   55.5 (35.5-65)    60.0 (44.2-64.6) NS
Previous liver surgery 13 (50) 5 (15.6)  0.009
Years between AE diagnosis and first biliary complication, (yr)     15.0 (8.3-19.0 ) NA
Age at first biliary complication, (yr)      64.5 (54.0-75.8) NA
Deaths during follow-up until 2006 15 (57.7) 5 (15.6) NA2
Liver related   5 1
Non-liver related 10 4
Age at death, (yr)    80.0 (67.5-81 )    78.5 (65.0-85.1) NS
Benzimidazole treatment (total) , (yr)    13.0 (8.1-20.0)    7.2 (4.2-16.1)    0.0404
Follow-up (total) , (yr)      23.0 (13.0-25.0)    8.6 (5.1-18.8) < 0.0001
Follow-up of survivors until study endpoint (end of 2006 or drop-out), (yr) 11 27
From AE diagnosis    - 24.0 (23.0-29.0)    7.1 (5.0-14.7)    0.0001
From biliary complication    - 9.0 (7.3-11.8)  NA
Follow-up until death, (yr) 15 5 NS
From AE diagnosis      15.0 (11.0-24.5)    21.2 (9.7-25.1 )
From biliary complication    2.0 (1.5-5.0)  NA
Data are expressed as absolute numbers (percentage) or median (quartiles). Comparison of patients with and without late biliary complications. 1For sta-
tistical analyses Fisher’s exact test was used for gender and outcome (death); for all other comparisons the Mann-Whitney U test was employed; 2Direct 
comparison is not appropriate at this point since time of follow up is different for both patient groups. After adjustment for this difference in the survival 
analysis (compare Figure 2), no significant difference remained. AE: Alveolar echinococcosis; NA: Not applicable; NS: No significant.
Biliary complication No. of patients Outcome 
Number deaths 
during follow-up
Time to death of 
non-survivors, (yr)
Length of follow-up 
after BC, (yr)
Sclerosing cholangitis-like lesions (subtype2)   8 (31)      7/8 (87.5)    3 (1.5-5)   3.75 (1.75-6)
Stenosis of the common bile duct (subtype 4)   7 (27)   4/7 (57)           4 (1.75-6.75)     6 (4-10)
Late cholangitis (subtype 1) 14 (54) 5/14 (35)    2 (2.5-6)          7 (4-10.25)
Hepatolithiasis (subtype 3)   5 (19)   3/5 (60) 2 (2-3)   4 (2-6)
Secondary biliary cirrhosis(subtype 5)   7 (27)   4/7 (57)    3 (2-4.5)   6 (3-7)
Postoperative biliary stenosis after hepaticojejunostomy (subtype 7) 1 (4) No deaths 11
Biliary fistula (subtype 8) 2 (8) No deaths   8
Since one patient can have more than one late biliary complication, numbers do not add up to 100%. Data are expressed as absolute numbers (percentage) 
or median (IQR).
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Table 4  Previous surgery and biliary complications
Table 3  Correlation and linear regression analysis for the risk of developing biliary complications
were AE induced liver failures. The ten other deaths 
were caused by infectious complications (n = 3), lethal 
gastrointestinal bleeding (n = 2), advanced age (n = 2) 
and cardiovascular diseases (n = 3). Overall, a substantial 
number of  deaths (8/15, 53%) were probably or likely 
linked to the AE infection (5 liver failures, 1 variceal 
bleed after secondary biliary cirrhosis and 2 septic 
shocks in patients with biliary cirrhosis). 7/17 deaths 
(47%) were not clearly liver-related or due to biliary 
complications.
Death occurred on average 3.0 (2-5) years after the 
diagnosis of  biliary complications.
The short time interval between the occurrence of  
late biliary complications and death underlines the prog-
nostic value of  such complications. However, survival 
after first diagnosis of  AE was not different in the bili-
ary complications group compared to the control group. 
Of  note, only 4 out of  7 patients with secondary biliary 
cirrhosis died (1 due to progressive liver disease after 
terminating treatment, 1 due to gastrointestinal bleeding, 
2 because of  septic shock). Five of  14 patients with late 
cholangitis died during follow-up.
Is the occurrence of a late biliary complication a poor 
prognostic sign?
To assess the prognostic relevance of  biliary complica-
tions, we compared the 26 patients with late biliary com-
plications to 32 control patients without biliary complica-
tions (Table 1). The control group included 27 patients 
with inoperable AE, 4 patients who had received non-cur-
ative surgery and 1 patient with a relapse after curatively 
intended AE surgery but no postoperative benzimidazole 
treatment due to non-compliance.
In the group with late biliary complications, sub-
stantially more patients died within the follow-up period 
until 2006 (57.5% vs 15.6%). However, the mean and 
median follow up time in patients with late biliary com-
plications was substantially longer than in control pa-
tients, leading to a possible bias. Nevertheless, the range 
of  follow-up in these patient groups was comparable. 
Moreover, as shown in Figure 2, the diagnosis of  a bili-
ary complication seemed to mark a turning point in the 
natural course of  the disease. When we compared the 
survival of  patients immediately after the occurance of  
biliary complications to the overall survival of  patients 
with and without biliary complications after AE diagno-
sis a much shorter survival became apparent (Figure 2B). 
When survival after biliary complications was compared 
to survival of  the control group, this difference reached 
statistical significance. In contrast, a comparison of  the 
groups with and without biliary complications after di-
agnosis of  AE showed no differences in survival. This 
is probably due to the much longer mean and median 
follow-up time in the biliary complication group (Table 1), 
Distribution of various late biliary complications among patients with and without previous surgery. None of these differences reached statistical signifi-
cance (Fisher’s exact test).
Pearson correlation Linear regression analysis
Variable number Variable Pearson correlation 
coefficients
P  value for Pearson 
correlation
Unadjusted regression 
coefficients
P  value for regression 
coefficients
1 Gender  0.049 NS   0.141 NS
2 Age at diagnosis of AE -0.146 NS Redundant -
3 Mebendazole treatment  0.403   0.001 Redundant -
4 Albendazole treatment -0.351   0.003  -0.037 0.016
5 Benzimidazole  treatment  0.274   0.019   0.030 0.013
6 Whether or not surgery was performed  0.370 0.02   0.354 0.031
7 Age at diagnosis of biliary complication -0.069 NS   0.001 NS
8 Years from diagnosis of AE until endpoint 
(either BC or end of follow up)
 0.198 NS  -0.024 NS
Pearson correlation coefficients show the interdependence between pairs of variables, positive values indicate correlation and negative values anticorrela-
tion. Regression coefficients from a multivariate linear-regression model are shown in column 5. Redundant variables (Var2 = Var7-Var8 and Var3 = Var5-
Var4) do not appear in regression coefficients. R-square of the regression model is: 0.291. P values (95%CI) for Pearson correlation and regression coeffi-
cients are also indicated.
Previous surgery (n  = 13) No previous surgery (n  = 13)
Late cholangitis 8 6
Sclerosing-cholangitis like lesions 2 6
Hepatolithiasis 3 2
Affection of big bile ducts 3 4
Secondary biliary cirrhosis 4 3
Postoperative biliary stenosis (after hepaticojejunostomy) 1 0
Biliary fistula 2 0
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leading to a possible bias. In summary, our data suggest 
that the occurrence of  biliary complications indicates a 
“turning point” in the natural course of  non-resectable 
AE and implies a poor prognosis after this timepoint.
DISCUSSION
AE is a severe infectious disease with relevant morbid-
ity despite substantial increases in life expectancy over 
the last three decades[5,7]. Diagnostic and therapeutic im-
provements include better imaging techniques, improve-
ments in surgical and perioperative strategies and the 
possibility of  indefinite treatment with benzimidazoles 
in patients with non-resectable AE. Our data from a 
large national AE cohort demonstrate that biliary com-
plications are a frequent problem in these patients in the 
course of  the disease. Despite prolonged life expectancy, 
our data show that late biliary complications may predict 
a poor prognostic outcome. Mortality after the occur-
rence of  biliary complications is substantially increased, 
with a median and mean survival of  only 3 and 3.6 years, 
respectively.
Literature on biliary complications in non-resectable 
AE is scarce. There are many case series on biliary com-
plications in “hydatid disease” (“cystic hydatid disease”), 
due to cystic echinococcosis, which differs from AE (“al-
veolar hydatid disease”) and shows a divergent biological 
behaviour. Thus, our study fills a gap in the knowledge 
of  the clinical course of  AE.
We tried to analyze potential risk factors for late bili-
ary complications in non-resectable AE. In our analysis, 
length of  benzimidazole treatment and previous liver 
surgery were associated with late biliary complica-
tions. The association of  benzimidazole treatment and 
late biliary complications cannot be equated with a 
causal relationship. However, linear regression analysis 
showed that surgical interventions are a risk factor for 
biliary complications, although late biliary complications 
ocurred both in patients with and without previous sur-
gery. According to the literature, liver surgery can be 
associated with perioperative complications, and biliary 
complications after hepatic resections are known to be 
associated with a high risk of  liver failure and operative 
mortality[15]. Indeed, other case series have shown that 
there is a learning curve in liver resections (for other in-
dications), accounting for up to 10% of  all postoperative 
biliary complications[16]. In a Turkish study, focussing 
on hydatid liver surgery (treatment of  cystic hydatid dis-
ease), biliary leakage occurred in 26% of  54 patients[17]. 
It should be noted that the frequency of  non-curative 
“debulking” resections in our cohort was high, but most 
of  these operations were performed several decades ago. 
Today it has become clear that such surgery should be 
avoided[18], in line with case series reporting postopera-
tive recurrences in 3 of  9 patients[19]. Although length of  
albendazole treatment was associated with biliary com-
plications in linear regression analysis, this seems dif-
ficult to explain. Of  note, the albendazole subgroup was 
very small, including only 5 (19%) patients, of  which 4 
had previously been treated with mebendazole.
Despite the known beneficial effect of  benzimida-
zoles on longterm survival[5,7], benzimidazoles seem to 
be unable to completely prevent biliary complications in 
non-resectable AE. Despite the regression or stabiliza-
tion of  lesions, 28% (26/94) of  patients in our study 
with non-resectable AE developed late cholestatic com-
plications such as cholestatic jaundice or cholangitis 3 to 
26 year after the initial diagnosis of  AE. In regression 
analysis, follow-up time was not associated with biliary 
complications. This suggests that our data are credible 
despite different mean and median follow-up times in 
the biliary complications and control group (mean fol-
low up 11 years vs 20.3 years, median follow up 8.6 years 
vs 32 years). However, the range of  follow-up was not 
substantially different. This makes it unlikely that differ-
ences in follow-up time are distorting the data.
The reasons for late cholestatic complications on 
benzimidazole treatment are probably multifactorial and 
not just a consequence of  previous surgery, larval prolif-
eration and biliary infiltration. Hypothetical explanations 
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Figure 2  Survival of patients with alveolar echinococcosis with and without late biliary complications. Survival of patients with and without late biliary com-
plications is shown over the course of 2 decades. Survival of the biliary complication group is shown either as time after diagnosis of alveolar echinococcosis (AE) 
(solid line) or time after diagnosis of the late biliary complication (dotted line). Survival after diagnosis of AE does not differ. In contrast, survival after diagnosis of the 
late biliary complication is significantly shorter compared to overall survival in the control group (P < 0.0001) and in patients with AE after initial diagnosis (P = 0.0002), 
Log-rank (Mantel-Cox) test.
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include malcompliance with benzimidazole treatment, 
which was not addressed in our study. However, in clini-
cal practice benzimidazole levels are measured regularly 
(usually 4 h after drug intake) making malcompliance an 
unlikely cause for most patients. Furthermore, inactive 
AE cysts may trigger a non-productive immunological 
reaction, resulting in progressive fibrosis. In another 
scenario, the altered bile duct anatomy after AE infiltra-
tion might promote secondary infections or duodenal 
reflux causing secondary inflammation and fibrosis. This 
would explain why benzimidazoles seem to be able to 
inhibit AE growth, but not always the occurrence of  AE 
complications such as biliary obstructions[19]. In any case, 
we are unable to determine whether benzimidazoles are 
only partially effective for the prevention of  biliary com-
plications or were started too late in the course of  the 
disease.
Our study has several strengths and limitations. A 
major strength is the considerable number of  affected 
patients who were evaluated in this nationwide prospec-
tive cohort and who followed a rigorous study protocol 
since 1980. A first limitation is that some of  the studied 
complications occurred many years before the current 
data analysis, not all details about specific procedures 
performed and their immediate complications could be 
retrieved. We therefore focused on the first occurrence 
of  biliary complications and death as major endpoints, 
for which a robust analysis could be performed despite 
these limitations. Second, follow-up times in patients 
with and without late biliary complications were sub-
stantially different. However, the range of  follow-up was 
comparable between the two groups, as discussed above. 
Third, our analysis has to remain descriptive in many as-
pects and cannot provide clear risk factors for late biliary 
complications. There are no “parasitic factors” which 
could be identified as risk factors for late biliary compli-
cations. One could speculate that the PNM stage might 
be crucial, but we did not have access to concise PNM 
data. Thus, previous surgical interventions stay as major 
risk factor for late biliary complications.
How should the knowledge of  biliary complications 
and their impact on  long term survival change our man-
agement of  non-resectable AE? It seems crucial that 
primary care physicians and gastroenterologists caring 
for such patients pay attention to the relevant risk of  late 
biliary complications under long-term benzimidazole 
treatment, which is no guarantee for symptom-free long-
term survival. After the detection of  biliary complica-
tions, patients might benefit from advanced treatment 
options and tertiary care centers should be consulted. 
Centers will consider the benefits and risks of  interven-
tional procedures including ERCP and PTCD in the 
treatment of  biliary complications. Furthermore, early 
liver transplantation in incurable symptomatic biliary AE 
has been suggested[20], which has so far only rarely been 
done due to insufficient available data. Nevertheless, 
an individual discussion about the risks and potential 
benefits of  liver transplantation with otherwise eligible 
patients can be considered.
In summary, we have been able to demonstrate in a 
large cohort of  patients with non-resectable AE that bil-
iary complications are a frequent problem despite long-
term chemotherapy with benzimidazoles. Late biliary 
complications occurred in nearly one third of  patients, 
with previous surgery as a main risk factor. The survival 
in patients after occurrence of  late biliary complications 
was short, with a median and mean survival of  only 3 
and 3.6 years. These data suggest that the occurrence of  
biliary complications can cause substantial morbidity and 
is associated with increased mortality.
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